|
KMID : 1001020130110020105
|
|
Korean Journal of Urological Oncology
2013 Volume.11 No. 2 p.105 ~ p.108
|
|
|
Optimal Cycles of Docetaxel-Based Systemic Chemotherapy in Men with Metastatic Castration-Resistant Prostate Cancer (CRPC)
|
|
Ahn Sung-Hoon
Park Seung-Chol
|
|
|
Abstract
|
|
|
|
Metastatic prostate cancer is initially treated with androgen deprivation therapy, which induces rapid decrease in bone pain and decrease in serum prostate specific antigen level. However, most of cases with prostate cancer eventually progress to castration-resistant prostate cancer within a median of 18-24 months. Docetaxel-based systemic chemotherapy is now the standard treatment for CRPC, based on the results of 2 phase III studies. However, the optimal cycles of docetaxel-based systemic chemotherapy for CRPC has not been defined. Herein, we present two cases of castration-resistant prostate cancer treated by docetaxel-based systemic chemotherapy and reviewed recent literatures.
|
|
|
KEYWORD
|
|
|
Prostate cancer, Chemotherapy
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|